e10vq
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark one)
T |
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2005 |
OR
o |
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . |
COMMISSION FILE NUMBER: 000-1029142
DYNAVAX TECHNOLOGIES CORPORATION
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
|
|
|
DELAWARE
|
|
33-0728374 |
(State or Other Jurisdiction of Incorporation or Organization)
|
|
(IRS Employer Identification No.) |
2929 Seventh St., Suite 100
Berkeley, CA 94710-2753
(Address Of The Registrants Principal Executive Offices)
Registrants Telephone Number, Including Area Code: (510) 848-5100
Indicate by check mark whether the registrant (1) has filed all reports required to be filed
by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes T No £
Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule
12b-2 of the Act). Yes £ No T
Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange
Act). Yes o No T
The number of shares of the Registrants Common Stock outstanding as of October 31, 2005
was 29,757,740.
INDEX
DYNAVAX TECHNOLOGIES CORPORATION
2
FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934
which are subject to a number of risks and uncertainties. All statements that are not historical
facts are forward-looking statements, including statements about our business strategy, our future
research and development, our preclinical and clinical product development efforts, our ability to
commercialize our product candidates, the timing of the introduction of our products, the effect of
GAAP accounting pronouncements, uncertainty regarding our future operating results and our
profitability, anticipated sources of funds and all plans, objectives, expectations and intentions.
These statements appear in a number of places and can be identified by the use of forward-looking
terminology such as may, will, should, expect, plan, anticipate, believe, estimate,
predict, future, intend, or certain or the negative of these terms or other variations or
comparable terminology, or by discussions of strategy.
Actual results may vary materially from those in such forward-looking statements as a result
of various factors that are identified in Item 2 Managements Discussion and Analysis of
Financial Condition and Results of Operations and elsewhere in this document. No assurance can be
given that the risk factors described in this Quarterly Report on Form 10-Q are all of the factors
that could cause actual results to vary materially from the forward-looking statements. All
forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. Readers
should not place undue reliance on these forward-looking statements and are cautioned that any such
forward-looking statements are not guarantees of future performance. We assume no obligation to
update any forward-looking statements.
This Quarterly Report on Form 10-Q includes trademarks and registered trademarks of Dynavax
Technologies Corporation. Products or service names of other companies mentioned in this Quarterly
Report on Form 10-Q may be trademarks or registered trademarks of their respective owners.
3
PART I. FINANCIAL STATEMENTS
ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Dynavax Technologies Corporation
Condensed Consolidated Balance Sheets
(In thousands, except per share amounts)
|
|
|
|
|
|
|
|
|
|
|
September 30, |
|
December 31, |
|
|
2005 |
|
2004 |
|
|
(unaudited) |
|
(Note 2) |
Assets |
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
19,168 |
|
|
$ |
16,590 |
|
Marketable securities |
|
|
31,561 |
|
|
|
49,254 |
|
Restricted cash |
|
|
408 |
|
|
|
408 |
|
Accounts receivable |
|
|
1,061 |
|
|
|
3,131 |
|
Prepaid expenses and other current assets |
|
|
1,806 |
|
|
|
1,396 |
|
|
|
|
|
|
|
|
Total current assets |
|
|
54,004 |
|
|
|
70,779 |
|
Property and equipment, net |
|
|
2,286 |
|
|
|
2,465 |
|
Other assets |
|
|
412 |
|
|
|
402 |
|
|
|
|
|
|
|
|
Total assets |
|
$ |
56,702 |
|
|
$ |
73,646 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities and stockholders equity |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
2,259 |
|
|
$ |
1,391 |
|
Accrued liabilities |
|
|
3,910 |
|
|
|
4,371 |
|
Deferred revenues |
|
|
|
|
|
|
1,000 |
|
|
|
|
|
|
|
|
Total current liabilities |
|
|
6,169 |
|
|
|
6,762 |
|
|
|
|
|
|
|
|
|
|
Deferred revenues, noncurrent |
|
|
750 |
|
|
|
6,750 |
|
Other long-term liabilities |
|
|
205 |
|
|
|
258 |
|
|
|
|
|
|
|
|
|
|
Commitments and contingencies (Note 3) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders equity: |
|
|
|
|
|
|
|
|
Preferred stock: $0.001 par value; 5,000 shares authorized and
no shares issued and outstanding at September 30, 2005 and
December 31, 2004 |
|
|
|
|
|
|
|
|
Common stock: $0.001 par value; 100,000 shares authorized at
September 30, 2005 and December 31, 2004; 24,758 and 24,627
shares issued and outstanding at September 30, 2005 and December
31, 2004, respectively |
|
|
25 |
|
|
|
25 |
|
Additional paid-in capital |
|
|
159,173 |
|
|
|
159,074 |
|
Deferred stock compensation |
|
|
(2,383 |
) |
|
|
(3,366 |
) |
Notes receivable from stockholders |
|
|
(8 |
) |
|
|
(419 |
) |
Accumulated other comprehensive loss: |
|
|
|
|
|
|
|
|
Unrealized loss on marketable securities available-for-sale |
|
|
(96 |
) |
|
|
(102 |
) |
Cumulative translation adjustment |
|
|
(4 |
) |
|
|
|
|
Accumulated deficit |
|
|
(107,129 |
) |
|
|
(95,336 |
) |
|
|
|
|
|
|
|
Total stockholders equity |
|
|
49,578 |
|
|
|
59,876 |
|
|
|
|
|
|
|
|
Total liabilities and stockholders equity |
|
$ |
56,702 |
|
|
$ |
73,646 |
|
|
|
|
|
|
|
|
See accompanying notes.
4
Dynavax Technologies Corporation
Condensed Consolidated Statements of Operations
(In thousands, except per share amounts)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Nine Months Ended |
|
|
September 30, |
|
September 30, |
|
|
2005 |
|
|
2004 |
|
|
2005 |
|
|
2004 |
|
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaboration revenue |
|
$ |
|
|
|
$ |
3,769 |
|
|
$ |
12,199 |
|
|
$ |
11,644 |
|
Grant revenue |
|
|
404 |
|
|
|
(109 |
) |
|
|
1,856 |
|
|
|
713 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues |
|
|
404 |
|
|
|
3,660 |
|
|
|
14,055 |
|
|
|
12,357 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
6,797 |
|
|
|
5,928 |
|
|
|
19,945 |
|
|
|
17,709 |
|
General and administrative |
|
|
2,319 |
|
|
|
2,017 |
|
|
|
7,132 |
|
|
|
6,013 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses |
|
|
9,116 |
|
|
|
7,945 |
|
|
|
27,077 |
|
|
|
23,722 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from operations |
|
|
(8,712 |
) |
|
|
(4,285 |
) |
|
|
(13,022 |
) |
|
|
(11,365 |
) |
Interest income, net |
|
|
428 |
|
|
|
252 |
|
|
|
1,229 |
|
|
|
557 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(8,284 |
) |
|
$ |
(4,033 |
) |
|
$ |
(11,793 |
) |
|
$ |
(10,808 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted net loss per share |
|
$ |
(0.33 |
) |
|
$ |
(0.16 |
) |
|
$ |
(0.48 |
) |
|
$ |
(0.54 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares used to compute basic and diluted net loss per share |
|
|
24,751 |
|
|
|
24,609 |
|
|
|
24,740 |
|
|
|
20,034 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes.
5
Dynavax Technologies Corporation
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended |
|
|
September 30, |
|
|
2005 |
|
2004 |
Operating activities |
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(11,793 |
) |
|
$ |
(10,808 |
) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
578 |
|
|
|
307 |
|
Loss on disposal of property and equipment |
|
|
|
|
|
|
18 |
|
Accretion and amortization on marketable securities |
|
|
850 |
|
|
|
80 |
|
Interest accrued on notes receivable from stockholders |
|
|
(16 |
) |
|
|
(29 |
) |
Amortization of stock-based compensation expense |
|
|
961 |
|
|
|
1,944 |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
2,070 |
|
|
|
(3,324 |
) |
Prepaid expenses and other current assets |
|
|
(410 |
) |
|
|
379 |
|
Other assets |
|
|
(10 |
) |
|
|
(389 |
) |
Accounts payable |
|
|
868 |
|
|
|
649 |
|
Accrued liabilities |
|
|
(461 |
) |
|
|
1,896 |
|
Deferred revenues |
|
|
(7,000 |
) |
|
|
7,250 |
|
|
|
|
|
|
|
|
Net cash used in operating activities |
|
|
(14,363 |
) |
|
|
(2,027 |
) |
|
|
|
|
|
|
|
Investing activities |
|
|
|
|
|
|
|
|
Purchases of marketable securities |
|
|
(39,203 |
) |
|
|
|
|
Maturities and sales of marketable securities |
|
|
56,052 |
|
|
|
5,549 |
|
Purchases of property and equipment |
|
|
(452 |
) |
|
|
(1,654 |
) |
|
|
|
|
|
|
|
Net cash provided by investing activities |
|
|
16,397 |
|
|
|
3,895 |
|
|
|
|
|
|
|
|
Financing activities |
|
|
|
|
|
|
|
|
Proceeds from issuance of common stock, net of issuance costs |
|
|
|
|
|
|
46,534 |
|
Proceeds from employee stock purchase plan |
|
|
115 |
|
|
|
|
|
Exercise of stock options |
|
|
6 |
|
|
|
|
|
Repayment of notes receivable from stockholders |
|
|
427 |
|
|
|
52 |
|
Restricted cash |
|
|
|
|
|
|
(408 |
) |
|
|
|
|
|
|
|
Net cash provided by financing activities |
|
|
548 |
|
|
|
46,178 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effect of exchange rate on cash and cash equivalents |
|
|
(4 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net increase in cash and cash equivalents |
|
|
2,578 |
|
|
|
48,046 |
|
Cash and cash equivalents at beginning of period |
|
|
16,590 |
|
|
|
23,468 |
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of period |
|
$ |
19,168 |
|
|
$ |
71,514 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental disclosure of non-cash investing and financing activities |
|
|
|
|
|
|
|
|
Net change in unrealized loss on marketable securities |
|
$ |
6 |
|
|
$ |
|
|
|
|
|
|
|
|
|
Change in cumulative translation adjustment |
|
$ |
(4 |
) |
|
$ |
|
|
|
|
|
|
|
|
|
Exercise of stock options |
|
$ |
200 |
|
|
$ |
|
|
|
|
|
|
|
|
|
Repurchase of common stock for exercise of stock options |
|
$ |
(200 |
) |
|
$ |
|
|
|
|
|
|
|
|
|
Conversion of preferred stock upon initial public offering |
|
$ |
|
|
|
$ |
83,635 |
|
|
|
|
|
|
|
|
Conversion of ordinary shares in Dynavax Asia upon initial public offering. |
|
$ |
|
|
|
$ |
14,733 |
|
|
|
|
|
|
|
|
See accompanying notes.
6
Dynavax Technologies Corporation
Notes to Condensed Consolidated Financial Statements
(Unaudited)
1. Organization
Dynavax Technologies Corporation (Dynavax or the Company) is a biopharmaceutical company
that discovers, develops, and intends to commercialize innovative products to treat and prevent
allergies, infectious diseases, and chronic inflammatory diseases. The Company was originally
incorporated in California on August 29, 1996 and reincorporated in Delaware on March 26, 2001.
In February 2004, the Company sold a total of 6,900,000 shares of its common stock, after
adjusting for a one-for-three reverse stock split, in an underwritten initial public offering,
raising net proceeds of approximately $46.5 million. The effect of the reverse stock split is
reflected in the Condensed Consolidated Financial Statements for all periods presented.
Subsidiaries
In October 2003, the Company formed Dynavax Asia Pte. Ltd. (Dynavax Asia), a 100% owned
subsidiary in Singapore which focuses on the Companys clinical and preclinical hepatitis B
programs. In December 2004, the Company formed Ryden Therapeutics KK (Ryden), a 100% owned Japan
subsidiary, to explore development and commercialization options for ISS-based immunotherapies for
cedar tree allergy in Japan.
2. Summary of Significant Accounting Policies
Basis of Presentation
Our accompanying unaudited Condensed Consolidated Financial Statements have been prepared in
accordance with generally accepted accounting principles for interim financial information and
pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X. In our opinion, these
unaudited Condensed Consolidated Financial Statements include all adjustments, consisting only of
normal recurring adjustments, which the Company considers necessary to fairly state our financial
position and the results of our operations and cash flows. Interim-period results are not
necessarily indicative of results of operations or cash flows for a full-year period. The balance
sheet at December 31, 2004 has been derived from audited financial statements at that date, but
does not include all disclosures required by U.S. generally accepted accounting principles for
complete financial statements.
These unaudited Condensed Consolidated Financial Statements and the notes accompanying them
should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31,
2004 as filed with the Securities and Exchange Commission (SEC) on March 18, 2005.
The Condensed Consolidated Financial Statements include the accounts of Dynavax, Dynavax Asia
and Ryden. All significant intercompany accounts and transactions have been eliminated. The Company
operates in one business segment, which is the development of biopharmaceutical products.
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally
accepted in the United States requires management to make estimates and assumptions that affect the
amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Actual
results may differ from these estimates.
Critical Accounting Policies
The Company believes that there have been no significant changes in its critical accounting
policies during the nine months ended September 30, 2005 as compared with those disclosed in its
Annual Report on Form 10-K for the year ended December 31, 2004.
7
Recent Accounting Pronouncements
On March 29, 2005, the SEC published Staff Accounting Bulletin (SAB) No. 107 regarding the
interaction between Financial Accounting Standard (FAS) No. 123R (revised 2004), Share-Based
Payment and certain SEC rules and regulations. The Financial Accounting Standards Board (FASB)
issued FAS No. 123R on December 16, 2004, that requires all share-based payments to employees,
including grants of employee stock options, to be recognized based on their fair values. Pro forma
disclosure is no longer an alternative. FAS No. 123R supersedes Accounting Principles Board (APB)
No. 25, Accounting for Stock Issued to Employees, and amends FAS No. 95, Statement of Cash
Flows.
Under FAS No. 123R, share-based payments to employees result in a cost that will be measured
at fair value on the awards grant date, based on the estimated number of awards that are expected
to vest. Compensation cost for awards that vest would not be reversed if the awards expire without
being exercised. When measuring fair value, companies can choose an option-pricing model (e.g.,
Black-Scholes or binomial models) that appropriately reflects their specific circumstances and the
economics of their transactions. Upon adoption of FAS No. 123R public companies are allowed to
select from alternative transition methods, each having different reporting implications. FAS No.
123R is effective for the fiscal year beginning after June 15, 2005, and applies to all outstanding
and unvested share-based payments as of the adoption date.
The Company will adopt FAS No. 123R as of January 1, 2006. The adoption of FAS No. 123Rs fair
value method will have a significant impact on our result of operations, although it will have no
impact on our overall financial position. The impact of adoption of FAS No. 123R cannot be
predicted at this time because the Company is in the process of reevaluating our methodology used
to determine fair value, including consideration of an option-pricing model and related
assumptions, and the method of adoption. In addition, the impact of adoption will depend on levels
of share-based payments granted in the future.
Stock-Based Compensation
As permitted under FAS No. 123, Accounting for Stock-Based Compensation as amended by FAS
No. 148, Accounting for Stock-Based Compensation Transition and Disclosure, the Company
continues to recognize employee stock compensation under the intrinsic value method of accounting
as prescribed by APB No. 25 and its interpretations. Under APB No. 25, compensation expense is
based on the difference, if any, between the estimated fair value of our common stock and the
option exercise price on the date of grant. The Company accounts for stock compensation to
non-employees in accordance with FAS No. 123, as amended by FAS No. 148 and EITF Issue 96-18,
Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in
Conjunction with Selling Goods or Services.
The following table illustrates the pro forma effect on our net loss and net loss per share as
if the Company had applied the fair value recognition provisions of FAS No. 123 to employee stock
compensation (in thousands, except per share amounts):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Nine Months Ended |
|
|
September 30, |
|
September 30, |
|
|
2005 |
|
2004 |
|
2005 |
|
2004 |
Net loss, as reported |
|
$ |
(8,284 |
) |
|
$ |
(4,033 |
) |
|
$ |
(11,793 |
) |
|
$ |
(10,808 |
) |
Add: Stock-based employee
compensation expense included in
net loss |
|
|
307 |
|
|
|
549 |
|
|
|
975 |
|
|
|
1,753 |
|
Less: Stock-based employee
compensation expense determined
under the fair value based method |
|
|
(739 |
) |
|
|
(745 |
) |
|
|
(2,156 |
) |
|
|
(2,242 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss, pro forma |
|
$ |
(8,716 |
) |
|
$ |
(4,229 |
) |
|
$ |
(12,974 |
) |
|
$ |
(11,297 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted net loss, as reported |
|
$ |
(0.33 |
) |
|
$ |
(0.16 |
) |
|
$ |
(0.48 |
) |
|
$ |
(0.54 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted net loss, pro forma |
|
$ |
(0.35 |
) |
|
$ |
(0.17 |
) |
|
$ |
(0.52 |
) |
|
$ |
(0.56 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Such pro forma disclosure may not be representative of future stock-based compensation expense
because such options vest over several years and additional grants may be made each year.
8
The estimated fair value of each option and employee purchase right is estimated on the date
of grant using the Black-Scholes option-pricing model, assuming no expected dividends and the
following weighted-average assumptions:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Employee Stock |
|
|
Employee Stock Options |
|
Purchase Plan |
|
|
Three Months Ended |
|
Nine Months Ended |
|
Nine Months Ended |
|
|
September 30, |
|
September 30, |
|
September 30, |
|
|
2005 |
|
2004 |
|
2005 |
|
2004 |
|
2005 |
|
2004 |
Weighted-average fair value |
|
$ |
3.42 |
|
|
$ |
4.75 |
|
|
$ |
3.82 |
|
|
$ |
5.54 |
|
|
$ |
2.15 |
|
|
$ |
3.21 |
|
Risk-free interest rate |
|
|
4.1 |
% |
|
|
3.1 |
% |
|
|
3.7 |
% |
|
|
3.0 |
% |
|
|
3.4 |
% |
|
|
2.0 |
% |
Expected life (in years) |
|
|
4 |
|
|
|
4 |
|
|
|
4 |
|
|
|
4 |
|
|
|
0.5 |
|
|
|
0.5 |
|
Volatility |
|
|
0.68 |
|
|
|
1.0 |
|
|
|
0.73 |
|
|
|
1.0 |
|
|
|
0.71 |
|
|
|
1.0 |
|
3. Commitments and Contingencies
The Company leases its facility under an operating lease that expires in September 2014. The
lease can be terminated by the Company at no cost in September 2009 but otherwise extends
automatically until September 2014.
Our facility lease agreement provides for periods of escalating rent. The total cash payments
over the life of the lease were divided by the total number of months in the lease period and the
average rent is charged to expense each month during the lease period. In addition, our lease
agreement provides a tenant improvement allowance of $0.4 million, which is considered a lease
incentive and accordingly, has been included in accrued liabilities and other long-term liabilities
in the Condensed Consolidated Balance Sheets as of September 30, 2005 and December 31, 2004. The
lease incentive is amortized as an offset to rent expense over the estimated initial lease term,
through September 2009. Total net rent expense related to this operating lease for the nine months
ended September 30, 2005 was $1.1 million. Deferred rent was $0.1 million as of September 30, 2005.
The Company has entered into a sublease agreement for a certain portion of the leased space
with scheduled payments to the Company of $339,990 annually through 2007. This sublease agreement
provides the Company an option for early termination in August 2006 but otherwise extends
automatically until August 2007.
Future minimum payments under the non-cancelable portion of our operating lease at September
30, 2005, excluding payments from the sublease agreement, are as follows (in thousands):
|
|
|
|
|
Year ending December 31, |
|
|
|
|
2005 |
|
$ |
421 |
|
2006 |
|
|
1,704 |
|
2007 |
|
|
1,755 |
|
2008 |
|
|
1,807 |
|
2009 |
|
|
1,231 |
|
|
|
|
|
|
|
$ |
6,918 |
|
|
|
|
|
During the fourth quarter of 2004, the Company established a letter of credit with Silicon
Valley Bank as security for our property lease in the amount of $0.4 million. The letter of credit
remained outstanding as of September 30, 2005 and is collateralized by a certificate of deposit
which has been included in restricted cash in the Condensed Consolidated Balance Sheets as of
September 30, 2005 and December 31, 2004. Under the terms of the lease agreement, if the total
amount of our cash, cash equivalents and marketable securities falls below $20.0 million for a
period of more than 30 consecutive days during the lease term, the amount of the required security
deposit will increase to $1.1 million, until such time as our projected cash and cash equivalents
will exceed $20.0 million for the remainder of the lease term, or until our actual cash and cash
equivalents remains above $20.0 million for a period of 12 consecutive months.
The Company relies on research institutions and contract research organizations that conduct
and manage clinical trials on our behalf. As of September 30, 2005, under the terms of our
agreements with a contract research organization (CRO) and clinical investigator, the Company is
obligated to make future payments as services are provided of up to $13.2 million through 2008.
These agreements are terminable by the Company upon written notice to the CRO and the Company is
only liable for actual effort expended by the CRO at any point in time during the contract.
The Company, as permitted under Delaware law and in accordance with its bylaws, indemnifies
its officers and directors for certain events or occurrences, subject to certain limits, while the
officers or directors are or were serving at the Companys
request in such capacity.
9
The term of the indemnification period is for each officer or directors
lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company
has a director and officer insurance policy that limits its exposure up to $10.0 million and may
enable the Company to recover a portion of any future amounts paid. The Company believes the
estimated fair value of these indemnification agreements is minimal. Accordingly, the Company has
no liabilities recorded for these agreements as of September 30, 2005.
The Company enters into indemnification provisions under its agreements with other companies
in its ordinary course of business, typically with business partners, contractors, clinical sites
and customers. Under these provisions, the Company generally indemnifies and holds harmless the
indemnified party for losses suffered or incurred by the indemnified party as a result of the
Companys activities relating to these contracts. These indemnification provisions generally
survive termination of the underlying agreement. In certain circumstances, the maximum potential
amount of future payments the Company could be required to make under these indemnification
provisions is unlimited. The Company has not incurred material costs to defend lawsuits or settle
claims related to these indemnification agreements. As a result, the estimated fair value of these
agreements is minimal. Accordingly, the Company has no liabilities recorded for these agreements as
of September 30, 2005.
4. Collaborative Research, Development, and License Agreements
UCB Farchim, S.A.
In March 2005, the Company agreed to end its collaboration with UCB Farchim, S.A. (UCB) and
regained full rights to its allergy program. During the quarter ended June 30, 2005, the Company
received cash payments in satisfaction of outstanding receivables due from UCB and obligations owed
by UCB under the collaboration. Collaboration revenue for the nine months ended September 30, 2005
included accelerated recognition of $7.0 million in deferred revenue as the Company had no ongoing
obligations under the collaboration and also included revenue associated with cash received
following the ending of the collaboration.
University of California
The Company entered into a series of exclusive license agreements with the Regents of the
University of California (UC) in March 1997 and October 1998. These agreements provide the Company
with certain technology and related patent rights and materials. Under the terms of the agreements,
the Company pays annual license or maintenance fees and will be required to pay milestones and
royalties on net sales of products originating from the licensed technologies. The agreements will
expire on either the expiration date of the last-to-expire patent licensed under the agreements or
the date upon which the last patent application licensed under the agreements is abandoned.
In connection with these license agreements, the Company incurred license fees of $20,000
during the first nine months of 2005 and 2004 which was recorded as research and development
expense, and the Company incurred patent expenses of $0.2 million and $0.3 million during the nine
months ended September 30, 2005 and 2004, respectively, which was recorded as general and
administrative expense. As partial consideration for the technology licenses, the Company also
incurred a $0.4 million one-time charge due upon the closing of the Companys initial public
offering in the first quarter of 2004, which was recorded as research and development expense.
Additionally, as partial consideration for the technology licenses, the Company paid $0.2 million
to UC related to the collaboration with UCB. During the nine months ended September 30, 2005, in
conjunction with the ending of the UCB collaboration, the Company incurred $0.1 million in research
and development expense from the accelerated amortization of the prepaid technology licenses fee.
BioSeek, Inc.
In June 2003, the Company entered into a development collaboration agreement with BioSeek,
Inc. to analyze and characterize the activity of certain compounds using BioSeeks technology with
the objective of advancing the development of such compounds. Under this agreement, the Company
will make various payments to BioSeek based on the success and timing of the Companys signing of a
third party partnering agreement where the Company grants to the third party, directly or
indirectly, any right or option to market, sell, distribute or otherwise commercialize a
thiazolopyrimidine (TZP) product in any geographic territory. During the nine months ended
September 30, 2005, the Company paid BioSeek $0.3 million associated with the achievement of a
contractual milestone.
10
Other Agreements
In the third quarter of 2003, the Company was awarded government grants totaling $8.4 million
to be received over as long as three and one-half years, assuming annual review criteria are met,
to fund research and development of certain biodefense programs. Revenue associated with these
grants is recognized as the related expenses are incurred. During the second quarter of 2005, the
indirect cost rate associated with these grants was approved by the National Institutes of Health.
As a result, grant revenue for the nine months ended September 30, 2005 included a one-time
increase of $0.5 million, reflecting the adjustment under the government grant awards from the
previously utilized minimum cost overhead rate allowable to the final approved rate.
In the fourth quarter of 2004, the Company was awarded $0.5 million from the Alliance for
Lupus Research to be received during 2005 and 2006 to fund research and development of new
treatment approaches for lupus. For the nine months ended September 30, 2005, the Company
recognized revenue of approximately $0.2 million associated with the lupus grant.
5. Net Income (Loss) Per Share
Basic net income (loss) per share is calculated by dividing net income (loss) for the period
by the weighted-average shares outstanding for that period. Diluted net income (loss) per share
takes into account the effect of diluted instruments, such as stock options and warrants, and uses
the average share price for the period in determining the number of incremental shares that are to
be added to the weighted-average number of shares outstanding.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Nine Months Ended |
|
|
September 30, |
|
September 30, |
|
|
2005 |
|
2004 |
|
2005 |
|
2004 |
Shares used to
compute basic and
diluted net income
(loss) per share |
|
|
24,751,479 |
|
|
|
24,609,156 |
|
|
|
24,739,697 |
|
|
|
20,033,426 |
|
Certain potentially dilutive shares were excluded from the shares used to compute diluted net
income (loss) per share since their inclusion would have been anti-dilutive, either because the
options exercise prices exceeded the average fair market value of the stock during the period or
due to the loss for the period.
6. Stockholders Equity
At September 30, 2005, there were 24,757,740 shares of our common stock issued and
outstanding. Activity under our stock option plans is set forth below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options |
|
|
|
|
|
|
Available |
|
Number of Options |
|
Weighted-Average |
|
|
for Grant |
|
Outstanding |
|
Price Per Share |
Balance at
December 31, 2004
(1,528,007 exercisable at
$2.55 weighted-average
price per share) |
|
|
3,342,976 |
|
|
|
1,828,314 |
|
|
$ |
3.17 |
|
Options authorized |
|
|
400,000 |
|
|
|
|
|
|
|
|
|
Options granted |
|
|
(808,400 |
) |
|
|
808,400 |
|
|
$ |
6.73 |
|
Options exercised |
|
|
|
|
|
|
(136,416 |
) |
|
$ |
1.51 |
|
Options canceled |
|
|
18,471 |
|
|
|
(18,471 |
) |
|
$ |
6.63 |
|
Shares repurchased |
|
|
27,817 |
|
|
|
|
|
|
$ |
7.19 |
|
Shares retired |
|
|
(27,817 |
) |
|
|
|
|
|
$ |
7.19 |
|
|
|
|
|
|
|
|
|
|
|
|
Balance at
September 30, 2005
(1,514,374 exercisable at
$3.01 weighted-average
price per share) |
|
|
2,953,047 |
|
|
|
2,481,827 |
|
|
$ |
4.40 |
|
|
|
|
|
|
|
|
|
|
|
|
In April 2005, in accordance with the terms of the 2004 Stock Incentive Plan, the Board of
Directors approved an increase of 400,000 shares of common stock available for grant. During the
nine months ended September 30, 2005, the Company issued 136,416 shares of common stock resulting
from option exercises, of which 27,817 shares were surrendered to the Company in lieu of cash
payment for the option exercise.
11
Employee and director stock-based compensation expense and non-employee stock-based
compensation expense for the three and nine months ended September 30, 2005 and 2004 were as
follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Nine Months Ended |
|
|
September 30, |
|
September 30, |
|
|
2005 |
|
2004 |
|
2005 |
|
2004 |
Employees and directors stock-based compensation expense |
|
$ |
307 |
|
|
$ |
549 |
|
|
$ |
975 |
|
|
$ |
1,753 |
|
Non-employees stock-based compensation expense |
|
|
1 |
|
|
|
179 |
|
|
|
(14 |
) |
|
|
191 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
308 |
|
|
$ |
728 |
|
|
$ |
961 |
|
|
$ |
1,944 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In April 2005, in accordance with the terms of the 2004 Employee Stock Purchase Plan (the
Purchase Plan), the Board of Directors approved an increase of 246,000 shares of common stock
available for purchase. During the nine months ended September 30, 2005, employees acquired 21,995
shares of our common stock. At September 30, 2005, 461,308 shares of our common stock remained
available for future purchases under the Purchase Plan.
Also in April 2005, the Company adopted a compensation plan for its Board of Directors in the
form of revisions to its 2004 Non-employee Director Option Program and 2004 Director Cash
Compensation Program. The plan generally provides that each director, other than the chair of the
board, receive an option to purchase 20,000 shares of common stock on April 14, 2005, subsequent
annual grants at the stockholders meeting (beginning with the 2006 meeting) of 10,000 shares each
year thereafter, a $20,000 annual retainer, and $2,000 for each in-person board meeting or $500 for
each telephonic board meeting attended. The plan also provides that the chair of the board receive
an option to purchase 30,000 shares of common stock on April 14, 2005, subsequent annual grants at
the stockholders meeting (beginning with the 2006 meeting) of 10,000 shares each year thereafter,
a $30,000 annual retainer, and $2,000 for each in-person board meeting or $500 for each telephonic
board meeting attended. In addition, the plan provides that the chair of the Audit Committee,
Compensation Committee and Nominating Committee receive an annual retainer of $15,000, $6,000 and
$3,000, respectively. Directors attending meetings of the Audit Committee will receive $1,500 per
in-person meeting or $500 per telephonic meeting. Directors attending meetings of the Compensation
and Nominating Committees will receive $1,000 per in-person meeting or $500 per telephonic meeting.
Certain of the Companys directors and their affiliates beneficially owned or controlled
approximately 12% of our outstanding common stock as of September 30, 2005. For the three and nine
months ended September 30, 2005, the Company incurred approximately $37,000 and $68,000,
respectively, in general and administrative expense associated with payments to these directors
under the compensation plan.
7. Related Party Transactions
From September 2000 through June 2001, the Company loaned $0.8 million to certain key
employees and officers for the exercise of incentive stock options. These are full recourse notes,
which accrue interest at rates ranging from 5.02% to 6.22% and are due through November 2005. The
shares of common stock held by the employees collateralize these notes. During the nine month
period ended September 30, 2005, approximately $0.4 million was repaid to the Company. As of
September 30, 2005, the remaining balance of the notes receivable from stock holders was
approximately $8,000.
8. Subsequent Events
On October 14, 2005 the Company announced the closing of an underwritten public offering of
5,000,000 shares of its common stock at a price of $6.25 per share. The offering was made under
the companys existing shelf registration statement, filed in August 2005, and resulted in net
proceeds to the company of approximately $29.4 million, after payment of underwriting discounts and
commissions, but excluding offering expenses. On November 10, 2005 the underwriters purchased an additional
720,000 shares through the exercise of an option granted in conjunction with the offering,
resulting in additional net proceeds to the company of approximately $4.2 million, after payment of
underwriting discounts and commissions, but excluding offering expenses. The offering, including the exercise of the
over-allotment option resulted in the total sale of
5,720,000 shares of the Companys common stock with net proceeds to the Company of approximately
$33.6 million, after payment of underwriting discounts and commissions, but excluding offering expenses.
12
ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following Managements Discussion and Analysis of Financial Condition and Results of
Operations contains forward-looking statements under federal securities laws. Forward-looking
statements are not guarantees of future performance and involve a number of risks and
uncertainties. Our actual results could differ materially from those indicated by forward-looking
statements as a result of various factors, including but not limited to those set forth under this
Item, as well as those discussed elsewhere in this document and those that may be identified from
time to time in our reports and registration statements filed with the Securities and Exchange
Commission.
This discussion should be read in conjunction with the Condensed Consolidated Financial
Statements and related Notes included in Item 1 of this quarterly report and the Consolidated
Financial Statements and related Notes and Managements Discussion and Analysis of Financial
Condition and Results of Operations contained in our Annual Report on Form 10-K as filed with the
Securities and Exchange Commission on March 18, 2005.
Overview
We discover, develop, and intend to commercialize innovative products to treat and prevent
allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary
approaches that alter immune system responses in highly specific ways. Our clinical development
programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that we
believe enhance the ability of the immune system to fight disease and control chronic inflammation.
The most advanced clinical programs in Dynavaxs ISS-based pipeline are a ragweed allergy
immunotherapeutic and a hepatitis B vaccine.
We have developed a novel injectable product candidate to treat ragweed allergy that we call
TOLAMBA (formerly, Amb a 1 ISS Conjugate or AIC). TOLAMBA has completed Phase II trials, and is
currently completing a two-year Phase II/III clinical trial. At the end of 2004, we reported that
the one-year interim analysis of this Phase II/III trial showed a clear positive trend relative to
the trials major endpoint of nasal symptom scores, as well as other secondary endpoints, following
the 2004 ragweed season. We intend to complete the Phase II/III clinical trial. In 2005, we
initiated a clinical trial in ragweed allergic children designed to support our planned Phase III
pivotal program. Pending the results of the Phase II/III study and the outcome of discussions with
the U.S. Food and Drug Administration (FDA), we plan to initiate a pivotal Phase III clinical
program in early 2006.
We have developed a product candidate for hepatitis B prophylaxis called HEPLISAV. A Phase
II/III trial in subjects who are more difficult to immunize with conventional vaccines conducted in
Singapore has been completed. Results from the final analysis of this trial showed statistically
significant superiority in protective antibody response and robustness of protective effect after
three vaccinations when compared to Engerix-B. Results from a Phase II clinical trial in healthy
adults conducted earlier in 2004 showed that HEPLISAV induced a more robust and durable antibody
response than Engerix-B. In June 2005, we initiated a pivotal Phase III trial in the older, more
difficult to immunize population in Asia. We anticipate initiating a second pivotal Phase III trial
in adults in Canada in the first half of 2006. We believe that strategic opportunities for HEPLISAV
exist in selected countries worldwide. Our initial commercialization strategies will likely target
these markets and focus on high-value, underserved populations. These populations include
pre-hemodialysis patients, HIV and HCV positive patients, other populations with compromised immune
systems as well as professionals in healthcare and law enforcement for whom achieving
seroprotection quickly is critical. In October, we announced the initiation of a US-based Phase 1
clinical trial of HEPLISAV in patients with end-stage renal failure (pre-hemodialysis).
We have an inhaled therapeutic product candidate for treatment of asthma, which has completed
a Phase IIa trial in Canada. We are performing additional preclinical work to optimize the route of
administration and regimen for the asthma clinical program and have postponed additional clinical
trials in asthma.
We are evaluating the potential of ISS to enhance the effect of monoclonal antibodies in
cancer therapies. We have conducted an open-label Phase I, dose-escalation trial of ISS in
combination with Rituximab in 20 patients with Non-Hodgkins lymphoma (NHL). Results of this study
showed dose dependent pharmacological activity without significant toxicity. A follow-up Phase II
trial of ISS with Rituximab in NHL is currently underway in 30 patients with histologically
confirmed CD20+, B-cell follicular NHL who have received at least one previous treatment regimen
for lymphoma. The primary objective is to assess the proportion of patients who are alive and
without disease progression one year after initiating Rituximab therapy. Mechanistic studies will
be performed to characterize the enhancement of antitumor activity by ISS.
13
For the nine months ended September 30, 2005, our net loss was $11.8 million, compared to
$10.8 million for the same period in 2004. Our year to date operating results for 2005 reflect the
financial impact resulting from the ending of our development and commercialization collaboration
with UCB Farchim, S.A. (UCB) that occurred in March 2005. Total revenues for the nine months ended
September 30, 2005 were $14.1 million, compared to $12.4 million for the same period in 2004.
During the nine month period of 2005, 87% of our revenues were derived from our collaboration
activities with UCB and the ending of our collaboration, while the remaining revenues were earned
from government and private agency grants. Our ability to generate future collaboration revenue
will be dependent on our ability to enter into new collaborative relationships.
As of September 30, 2005, we had an accumulated deficit of $107.1 million. We do not have any
products that generate revenue. We expect to incur substantial and increasing losses as we continue
the development of our lead product candidates and preclinical and research programs. If we were to
receive regulatory approval for any of our product candidates, we would be required to invest
significant capital to develop, or otherwise secure through collaborative relationships, commercial
scale manufacturing, marketing and sales capabilities. Even if we are able to obtain approval for
our product candidates, we are likely to incur increased operating losses until product sales grow
sufficiently to support the organization.
In October 2005 we raised proceeds of approximately $29.4 million, net of underwriting
discounts and commissions, but excluding offering expenses, in an underwritten public offering of
5,000,000 shares of common stock. In November the underwriters of the offering exercised an option
to purchase an additional 720,000 shares of common stock to cover over-allotments resulting in additional
proceeds of approximately $4.2 million, net of underwriting discounts and commissions, but
excluding offering expenses. We intend to use the proceeds from this offering for general corporate
purposes, including clinical trials, research and development expenses and general and
administrative expenses.
For the year ended December 31, 2005, excluding the potential impact of any business
collaborations or other transactions that may be entered into, we anticipate that our operating
expenses will increase as compared to prior year in connection with our clinical development
activities and overall organizational growth.
Critical Accounting Policies and the Use of Estimates
The Company believes that there have been no significant changes in its critical accounting
policies during the nine months ended September 30, 2005 as compared with those disclosed in its
Annual Report on Form 10-K for the year ended December 31, 2004.
Results of Operations
The following table sets forth the results of operations for the quarters ended September 30,
2005 and 2004 (in thousands, except percentages):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Increase (Decrease) |
|
Nine Months Ended |
|
Increase (Decrease) |
|
|
September 30, |
|
from 2005 to 2004 |
|
September 30, |
|
from 2005 to 2004 |
Results of Operations: |
|
2005 |
|
2004 |
|
$ |
|
% |
|
2005 |
|
2004 |
|
$ |
|
% |
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaboration revenue |
|
$ |
|
|
|
$ |
3,769 |
|
|
$ |
(3,769 |
) |
|
|
(100 |
)% |
|
$ |
12,199 |
|
|
$ |
11,644 |
|
|
$ |
555 |
|
|
|
5 |
% |
Grant revenue |
|
|
404 |
|
|
|
(109 |
) |
|
|
513 |
|
|
|
471 |
% |
|
|
1,856 |
|
|
|
713 |
|
|
|
1,143 |
|
|
|
160 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues |
|
$ |
404 |
|
|
$ |
3,660 |
|
|
$ |
(3,256 |
) |
|
|
(89 |
)% |
|
$ |
14,055 |
|
|
$ |
12,357 |
|
|
$ |
1,698 |
|
|
|
14 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
$ |
6,797 |
|
|
$ |
5,928 |
|
|
$ |
869 |
|
|
|
15 |
% |
|
$ |
19,945 |
|
|
$ |
17,709 |
|
|
$ |
2,236 |
|
|
|
13 |
% |
General and administrative |
|
|
2,319 |
|
|
|
2,017 |
|
|
|
302 |
|
|
|
15 |
% |
|
|
7,132 |
|
|
|
6,013 |
|
|
|
1,119 |
|
|
|
19 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses |
|
$ |
9,116 |
|
|
$ |
7,945 |
|
|
$ |
1,171 |
|
|
|
15 |
% |
|
$ |
27,077 |
|
|
$ |
23,722 |
|
|
$ |
3,355 |
|
|
|
14 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income, net |
|
$ |
428 |
|
|
$ |
252 |
|
|
$ |
176 |
|
|
|
70 |
% |
|
$ |
1,229 |
|
|
$ |
557 |
|
|
$ |
672 |
|
|
|
121 |
% |
Revenues
Total revenues of approximately $0.4 million for the three months ended September 30, 2005
declined by $3.3 million compared to the same period in 2004, primarily resulting from the loss of
collaboration revenue derived from our agreement with UCB as discussed below.
14
Total revenues of
$14.1 million for the nine months ended September 30, 2005
increased by $1.7 million compared to the same period in 2004. Revenues for the first nine months of 2005 were comprised
of $12.2 million from our collaboration activities including ending our collaboration with UCB and
$1.9 million from government and private agency grants.
In March 2005, we agreed to end the collaboration with UCB and regained full rights to our
allergy program. During the quarter ended June 30, 2005, we received cash payments in satisfaction
of outstanding receivables due from UCB and obligations owed by UCB under the collaboration.
Collaboration revenue for the nine months ended September 30, 2005 included accelerated recognition
of $7.0 million in deferred revenue as we had no ongoing obligations under the collaboration and
also included revenue associated with cash received following the ending of the collaboration. Our
ability to generate future collaboration revenue and obtain additional capital will be dependent on
our ability to enter into new collaborative relationships. Until we enter into new collaboration
arrangements, we expect our future revenues will be limited to government and private agency
grants, which will be significantly lower than during the period when we had our collaboration
agreement with UCB.
During the second quarter of 2005, the indirect cost rate associated with our grants from the
National Institutes of Health was approved. As a result, the grant revenue for the nine months
ended September 30, 2005 included an increase of $0.5 million, reflecting the adjustment under the
government grant awards from the previously utilized minimum cost overhead rate allowable to the
final approved rate.
15
Research and Development
Research and development expense consists primarily of outside services related to our
preclinical experiments and clinical trials, regulatory filings, manufacturing our product
candidates for our preclinical experiments and clinical trials; compensation and related personnel
costs which include benefits, recruitment, travel and supply costs; allocated facility costs and
non-cash stock-based compensation. We expense our research and development costs as they are
incurred.
The following is a summary of our research and development expense (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Increase (Decrease) |
|
Nine Months Ended |
|
Increase (Decrease) |
|
|
September 30, |
|
from 2005 to 2004 |
|
September 30, |
|
from 2005 to 2004 |
Research and development: |
|
2005 |
|
2004 |
|
$ |
|
% |
|
2005 |
|
2004 |
|
$ |
|
% |
Compensation and
related personnel costs |
|
$ |
2,162 |
|
|
$ |
1,613 |
|
|
$ |
549 |
|
|
|
34 |
% |
|
$ |
6,505 |
|
|
$ |
4,806 |
|
|
$ |
1,699 |
|
|
|
35 |
% |
Outside services |
|
|
3,571 |
|
|
|
3,360 |
|
|
|
211 |
|
|
|
6 |
% |
|
|
10,338 |
|
|
|
10,259 |
|
|
|
79 |
|
|
|
1 |
% |
Facility costs |
|
|
922 |
|
|
|
611 |
|
|
|
311 |
|
|
|
51 |
% |
|
|
2,678 |
|
|
|
1,577 |
|
|
|
1,101 |
|
|
|
70 |
% |
Non-cash stock-based
compensation |
|
|
142 |
|
|
|
344 |
|
|
|
(202 |
) |
|
|
(59 |
)% |
|
|
424 |
|
|
|
1,067 |
|
|
|
(643 |
) |
|
|
(60 |
)% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total research and
development |
|
$ |
6,797 |
|
|
$ |
5,928 |
|
|
$ |
869 |
|
|
|
15 |
% |
|
$ |
19,945 |
|
|
$ |
17,709 |
|
|
$ |
2,236 |
|
|
|
13 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development expenses of $6.8 million and $20.0 million for the three and nine
months ended September 30, 2005 increased by $0.9 million, or 15%, and $2.2 million, or 13%,
respectively, from the same periods in 2004. The increase over the prior year was primarily due to
increased compensation and related personnel costs attributed to organizational growth. In
addition, allocated rent and operating costs for our facility rose from the prior year. Outside
costs for research, clinical trial and clinical manufacturing increased for the three months ended
September 30, 2005 primarily associated with our ragweed allergy and hepatitis B vaccine programs.
During 2005, we anticipate that our research and development expense will increase as compared
to prior year, in connection with our growing clinical development programs, including the TOLAMBA
trial in ragweed allergic children designed to support our planned Phase III pivotal program and
the Phase III clinical trial for our hepatitis B vaccine initiated in mid-2005.
General and Administrative
General and administrative expense consists primarily of compensation and related personnel
costs, outside services such as accounting, consulting, investor relations and insurance, legal and
patent costs, allocated facility costs and non-cash stock-based compensation.
The following is a summary of our general and administrative expense (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Increase (Decrease) |
|
Nine Months Ended |
|
Increase (Decrease) |
|
|
September 30, |
|
from 2005 to 2004 |
|
September 30, |
|
from 2005 to 2004 |
General and administrative: |
|
2005 |
|
2004 |
|
$ |
|
% |
|
2005 |
|
2004 |
|
$ |
|
% |
Compensation and
related personnel costs |
|
$ |
1,110 |
|
|
$ |
807 |
|
|
$ |
303 |
|
|
|
38 |
% |
|
$ |
3,353 |
|
|
$ |
2,454 |
|
|
$ |
899 |
|
|
|
37 |
% |
Outside services |
|
|
657 |
|
|
|
379 |
|
|
|
278 |
|
|
|
73 |
% |
|
|
1,931 |
|
|
|
1,270 |
|
|
|
661 |
|
|
|
52 |
% |
Legal and patent costs, net |
|
|
258 |
|
|
|
306 |
|
|
|
(48 |
) |
|
|
(16 |
)% |
|
|
935 |
|
|
|
849 |
|
|
|
86 |
|
|
|
10 |
% |
Facility costs |
|
|
128 |
|
|
|
141 |
|
|
|
(13 |
) |
|
|
(9 |
)% |
|
|
376 |
|
|
|
563 |
|
|
|
(187 |
) |
|
|
(33 |
)% |
Non-cash stock-based
compensation |
|
|
166 |
|
|
|
384 |
|
|
|
(218 |
) |
|
|
(57 |
)% |
|
|
537 |
|
|
|
877 |
|
|
|
(340 |
) |
|
|
(39 |
)% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total general and
administrative |
|
$ |
2,319 |
|
|
$ |
2,017 |
|
|
$ |
302 |
|
|
|
15 |
% |
|
$ |
7,132 |
|
|
$ |
6,013 |
|
|
$ |
1,119 |
|
|
|
19 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General and administrative expenses of $2.3 million and $7.1 million for the three and nine
months ended September 30, 2005 increased by $0.3 million, or 15%, and $1.1 million, or 19%,
respectively, from the same periods in 2004. The increase over the prior year primarily reflects
higher compensation and related benefits associated with the expansion of our management team and
overall organizational growth. In addition, outside services, including administrative, accounting
and consulting fees, increased primarily as a result of the review and testing of our internal
control systems in compliance with the requirements of the Sarbanes-Oxley Act. Legal and patent-related costs
during the nine months ended September 30, 2005 were net of $0.2
million in reimbursable patent interference costs.
During 2005, we expect
general and administrative expenses to increase as compared to prior
year, primarily resulting from the full year impact of organizational growth that occurred in 2004
and expenses incurred to support public company compliance requirements.
16
Interest Income, Net
Interest income, net of interest expense and amortization of premiums on marketable
securities, was $0.4 million and $1.2 million for the three and nine months ended September 30,
2005, respectively, compared to $0.3 million and $0.6 million for the three and nine months ended
September 30, 2004, respectively. The increase was primarily due to the investment of proceeds from
our initial public offering in higher yielding marketable securities in 2005.
Recent Accounting Pronouncements
On March 29, 2005, the SEC published Staff Accounting Bulletin (SAB) No. 107 regarding the
interaction between Financial Accounting Standard (FAS) No. 123R (revised 2004), Share-Based
Payment and certain SEC rules and regulations. The Financial Accounting Standards Board (FASB)
issued FAS No. 123R on December 16, 2004, that requires all share-based payments to employees,
including grants of employee stock options, to be recognized based on their fair values. Pro forma
disclosure is no longer an alternative. FAS No. 123R supersedes Accounting Principles Board (APB)
No. 25, Accounting for Stock Issued to Employees, and amends FAS No. 95, Statement of Cash
Flows.
Under FAS No. 123R, share-based payments to employees result in a cost that will be measured
at fair value on the awards grant date, based on the estimated number of awards that are expected
to vest. Compensation cost for awards that vest would not be reversed if the awards expire without
being exercised. When measuring fair value, companies can choose an option-pricing model (e.g.,
Black-Scholes or binomial models) that appropriately reflects their specific circumstances and the
economics of their transactions. Upon the adoption of FAS No. 123R public companies are allowed to
select from three alternative transition methods, each having different reporting implications. FAS
No. 123R is effective for the fiscal year beginning after June 15, 2005, and applies to all
outstanding and unvested share-based payments as of the adoption date.
We will adopt FAS No. 123R as of January 1, 2006. The adoption of FAS No. 123Rs fair value
method will have a significant impact on our result of operations, although it will have no impact
on our overall financial position. The impact of adoption of FAS No. 123R cannot be predicted at
this time because we are in the process of reevaluating our methodology used to determine fair
value, including consideration of an option-pricing model and related assumptions, and the method
of adoption. In addition, the impact of adoption will depend on levels of share-based payments
granted in the future.
Liquidity and Capital Resources
We have financed our operations since inception primarily through the sale of shares of our
common stock, shares of our convertible preferred stock, and ordinary shares in a subsidiary, which
have yielded a total of approximately $144.8 million in net cash proceeds and, to a lesser extent,
through amounts received under collaborative agreements and government grants for biodefense
programs. We completed an initial public offering in February 2004, raising net proceeds during
fiscal 2004 of approximately $46.5 million from the sale of 6,900,000 shares of common stock. As of
September 30, 2005, we had $50.7 million in cash, cash equivalents and marketable securities. Our
funds are currently invested in a variety of securities, including highly liquid institutional
money market funds, commercial paper, government and non-government debt securities and corporate
obligations.
Cash used in operating activities of $14.4 million during the nine months ended September 30,
2005 compared to $2.0 million for the same period in 2004. The variance from the prior year was due
primarily to the one-time $8.0 million upfront payment made to us by UCB in 2004 and a decline in
working capital.
Cash provided by investing activities of $16.4 million during the nine months ended September
30, 2005 compared $3.9 million for the same period in 2004. The variance from the prior year was
due primarily to net maturity of investments.
17
Cash provided by financing activities of $0.5 million during the nine months ended September
30, 2005 compared to $46.2 million for the same period in 2004. Cash provided by financing
activities during the first half of 2004 resulted primarily from the issuance of common stock in
our initial public offering.
In October 2005, we raised proceeds of approximately $29.4 million, net of underwriting
discounts and commissions, but excluding offering expenses, from the sale of 5,000,000 shares of
our common stock at a price of $6.25 per share. In November the underwriters purchased an
additional 720,000 shares through the exercise of an option granted in conjunction with the
offering, resulting in additional net proceeds to the company of approximately $4.2 million, after payment of
underwriting discounts and commissions, but excluding offering expenses. The offering, including the exercise of the
over-allotment option resulted in the total sale of
5,720,000 shares of the Companys common stock with net proceeds to the Company of approximately
$33.6 million, after payment of underwriting discounts and commissions, but excluding offering expenses. Due to this equity offering
we expect our cash, cash equivalents and marketable securities to increase from September 30, 2005 to December 31, 2005,
partially offset by continued use of cash for operations.
We believe our existing capital resources will be adequate to satisfy our capital needs for at
least the next twelve months. Because of the significant time it will take for any of our product
candidates to complete the clinical trials process, be approved by regulatory authorities and
successfully commercialized, we may require substantial additional capital resources. We may raise
additional funds through public or private equity offerings, debt financings, capital lease
transactions, corporate collaborations or other means. We may attempt to raise additional capital
due to favorable market conditions or strategic considerations even if we have sufficient funds for
planned operations.
Additional financing may not be available on acceptable terms, if at all. Capital may become
difficult or impossible to obtain due to poor market or other conditions that are outside of our
control. If at any time sufficient capital is not available, either through existing capital
resources or through raising additional funds, we may be required to delay, scale back or eliminate
some or all of our research or development programs, to lose rights under existing licenses or to
relinquish greater or all rights to product candidates at an earlier stage of development or on
less favorable terms than we would otherwise choose or may adversely affect our ability to operate
as a going concern.
Contractual Obligations
The following summarizes our significant contractual obligations as of September 30, 2005 and
the effect those obligations are expected to have on our liquidity and cash flow in future periods
(in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payments Due by Period |
Contractual Obligations: |
|
Total |
|
Less than 1 Year |
|
1-3 Years |
|
4-5 Years |
Future minimum payments under our operating lease |
|
$ |
6,918 |
|
|
$ |
421 |
|
|
$ |
3,459 |
|
|
$ |
3,038 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
6,918 |
|
|
$ |
421 |
|
|
$ |
3,459 |
|
|
$ |
3,038 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
We lease our facility under an operating lease that expires in September 2014. The lease
can be terminated at no cost to us in September 2009 but otherwise extends automatically until
September 2014. We have entered into a sublease agreement for a certain portion of the leased space
with scheduled payments to us of $339,990 annually through 2007. This sublease agreement provides
the Company an option for early termination in August 2006 but otherwise extends automatically
until August 2007.
The table above excludes certain commitments that are contingent upon future events. The most
significant of these contractual commitments that we consider to be contingent obligations are
summarized below.
During the fourth quarter of 2004, we established a letter of credit with Silicon Valley Bank
as security for our property lease in the amount of $0.4 million. The letter of credit remained
outstanding as of September 30, 2005 and is collateralized by a certificate of deposit which has
been included in restricted cash in the Condensed Consolidated Balance Sheets as of September 30,
2005 and December 31, 2004. Under the terms of the lease agreement, if the total amount of our
cash, cash equivalents and marketable securities falls below $20.0 million for a period of more
than 30 consecutive days during the lease term, the amount of the required security deposit will
increase to $1.1 million, until such time as our projected cash and cash equivalents will exceed
$20.0 million for the remainder of the lease term, or until our actual cash and cash equivalents
remains above $20.0 million for a period of 12 consecutive months.
We rely on research institutions and contract research organizations that conduct and manage
clinical trials on our behalf. As of September 30, 2005, under the terms of our agreements with a
contract research organization (CRO) and clinical investigator, we are obligated to make future
payments as services are provided of up to $13.2 million through 2008. These agreements are
terminable by us upon written notice to the CRO and we are only liable for actual effort expended
by the CRO at any point in time during the contract.
18
In March 2005, we agreed to end the collaboration with UCB and regained full rights to our
allergy program. We assume financial responsibility for all further clinical, regulatory,
manufacturing and commercial activities related to TOLAMBA and for preclinical development programs
in grass and in peanut allergy. During the quarter ended June 30, 2005, we received cash payments
in satisfaction of outstanding receivables due from UCB and obligations owed by UCB under the
collaboration. The March 2005 agreement also provides for the continued partial reimbursement of
certain patent interference fees and expenses, if and as incurred by the Company, subject to a
maximum amount.
Under the terms of the exclusive license agreements with the Regents of the University of
California, we are obligated to pay annual license or maintenance fees and will be required to pay
future milestones and royalties on net sales of products originating from the licensed
technologies. As partial consideration for the technology licenses, during the first quarter of
2004 we paid one-time charges of $0.4 million upon the closing of the Companys initial public
offering and $0.2 million related to the collaboration with UCB. No other milestones were achieved
as of September 30, 2005.
Under the development collaboration agreement with BioSeek, Inc., we will make various
payments based on the success and timing of the Companys signing of a third party partnering
agreement where the Company grants to the third party, directly or indirectly, any right or option
to market, sell, distribute or otherwise commercialize a thiazolopyrimidine (TZP) product in any
geographic territory. During the nine months ended September 30, 2005, we paid BioSeek $0.3 million
associated with the achievement of a contractual milestone.
Under the terms of an agreement with Berna Biotech, we agreed to make certain
commercialization and sales milestone payments to Berna regarding the Companys hepatitis B
vaccine. None of these milestones were achieved as of September 30, 2005.
Risk Factors
Various statements in this Quarterly Report on Form 10-Q are forward-looking statements
concerning our future products, expenses, revenues, liquidity and cash needs, as well as our plans
and strategies. These forward-looking statements are based on current expectations and we assume no
obligation to update this information. Numerous factors could cause our actual results to differ
significantly from the results described in these forward-looking statements, including the
following risk factors.
We have incurred substantial losses since inception and do not have any commercial products that generate revenue.
We have experienced significant operating losses in each year since our inception in August
1996. To date, our revenue has resulted from a collaboration agreement with UCB Farchim, S.A. (UCB)
and government and private agency grants. The UCB collaboration agreement ended in March 2005. The
grants are subject to annual review based on the achievement of milestones and other factors and
will terminate in January 2007 at the latest. Our accumulated deficit was $107.1 million as of
September 30, 2005, and we anticipate that we will incur substantial additional operating losses
for the foreseeable future. These losses have been, and will continue to be, principally the result
of the various costs associated with our research and development activities. We expect our losses
to increase primarily as a consequence of our continuing product development efforts.
We do not have any products that generate revenue. In 2005, we continued a Phase II/III trial
for TOLAMBA, an immunotherapy for ragweed allergy, and completed a Phase II/III trial for HEPLISAV
in Singapore. In 2005, we also initiated a trial of TOLAMBA in ragweed allergic children designed
to support our planned pivotal Phase III program and initiated a pivotal Phase III trial for
HEPLISAV. These and our other product candidates may never be commercialized, and we may never
generate product-related revenue. Our ability to generate product revenue depends upon:
|
|
|
demonstrating in clinical trials that our product candidates are safe and
effective, in particular, in the planned pivotal Phase III trials for TOLAMBA, the current
Phase III trial of HEPLISAV, the planned additional Phase III trials in HEPLISAV; |
|
|
|
|
obtaining regulatory approvals for our product candidates in the United States
and international markets; |
|
|
|
|
entering into collaborative relationships on commercially reasonable terms for
the development, manufacturing, sales and marketing of our product candidates, and then
successfully managing these relationships; and |
|
|
|
|
obtaining commercial acceptance of our products, in particular TOLAMBA and
HEPLISAV. |
19
If we are unable to generate revenues or achieve profitability, we may be required to
significantly reduce or discontinue our operations or raise additional capital under adverse
circumstances.
If we are unable to secure additional funding, we will have to reduce or discontinue operations.
We believe our existing capital resources will be adequate to satisfy our capital needs for at
least the next twelve months. Because of the significant time and resources it will take to develop
our product candidates, potentially commercialize them and generate revenues, we may require
substantial additional capital resources in order to continue our operations, and any such funding
may not cover our costs of operations. In the event we change our development plans or clinical
programs, we may need additional capital sooner than we currently anticipate.
We expect capital outlays and operating expenditures to increase over the next several years
as we expand our operations. We may be unable to obtain additional capital from financing sources
or from agreements with collaborators on acceptable terms, or at all. If at any time sufficient
capital is not available, we may be required to delay, reduce the scope of, or eliminate some or
all of our research, preclinical or clinical programs or discontinue our operations.
All of our product candidates are unproven, and our success depends on our product candidates being approved through uncertain and time-consuming regulatory processes. Failure to prove our products safe and effective in clinical trials and obtain regulatory approvals could require us to discontinue operations.
None of our product candidates has been proven safe and effective in clinical trials or
approved for sale in the United States or any foreign market. Any product candidate we develop is
subject to extensive regulation by federal, state and local governmental authorities in the United
States, including the FDA, and by foreign regulatory agencies. Our success is primarily dependent
on our ability to obtain regulatory approval for TOLAMBA, our ragweed allergy product candidate,
and HEPLISAV, our hepatitis B vaccine product candidate. Approval processes in the United States
and in other countries are uncertain, take many years and require the expenditure of substantial
resources. Product development failure can occur at any stage of clinical trials and as a result of
many factors, many of which are not under our control.
We will need to demonstrate in clinical trials that each product candidate is safe and
effective before we can obtain the necessary approvals from the FDA and foreign regulatory
agencies. We initiated a two-year, multi-site Phase II/III trial in the first quarter of 2004 in
the United States for TOLAMBA. We currently expect data from this trial in the early part of 2006;
however, we cannot guarantee that results from this trial will be positive. Although we have not
obtained data from the two-year Phase II/III trial, we initiated a trial of TOLAMBA in ragweed
allergic children designed to support our planned pivotal Phase III program. If we do not obtain
positive data from the two-year Phase II/III trial, or if we identify any safety issues associated
with TOLAMBA, we may be forced to terminate or suspend our ongoing pediatric trial, and pending the
outcome of discussions with the FDA, we may be delayed or prevented from initiating our planned
pivotal Phase III trial for TOLAMBA in early 2006. We have initiated a pivotal Phase III trial for
HEPLISAV in Asia. We anticipate initiating a second pivotal Phase III trial for HEPLISAV in Canada
in the first half of 2006. The FDA or foreign regulatory agencies may require us to conduct
additional clinical trials prior to approval in their jurisdictions.
Many new drug candidates, including many drug candidates that have completed Phase III
clinical trials, have shown promising results in early clinical trials and subsequently failed to
establish sufficient safety and efficacy to obtain regulatory approval. Despite the time and money
expended, regulatory approvals are never guaranteed. Failure to complete clinical trials and prove
that our products are safe and effective would have a material adverse effect on our ability to
eventually generate revenues and could require us to reduce the scope of or discontinue our
operations.
Our clinical trials may be suspended, delayed or terminated at any time. Even short delays in the commencement and progress of our trials may lead to substantial delays in the regulatory approval process for our product candidates, which will impair our ability to generate revenues.
We may suspend or terminate clinical trials at any time for various reasons, including
regulatory actions by the FDA or foreign regulatory agencies, actions by institutional review
boards, failure to comply with good clinical practice requirements, concerns regarding health risks
to test subjects, or inadequate supply of the product candidate. In addition, our ability to
conduct clinical trials for some of our product candidates, notably TOLAMBA, is limited due to the
seasonal nature of ragweed allergy. Even a small delay in a trial for any product candidate could
require us to delay commencement of the trial until the next appropriate season, which could result
in a delay of an entire year. For example,
20
if we are unable to initiate our planned pivotal Phase
III program for TOLAMBA by mid 2006, or if we do not receive FDA concurrence relative to the design
of our planned pivotal Phase III we would not be able to file
for registration in late 2007. Accordingly, the earliest we would be able to file for registration
is late 2008. Consequently, we may experience additional delays in obtaining regulatory approval
for these product candidates.
Suspension, termination or unanticipated delays of our clinical trials for TOLAMBA or HEPLISAV
may:
|
|
|
adversely affect our ability to commercialize or market any product candidates we may develop; |
|
|
|
|
impose significant additional costs on us; |
|
|
|
|
potentially diminish any competitive advantages that we may attain; |
|
|
|
|
adversely affect our ability to enter into collaborations, receive milestone payments or royalties |
|
|
|
|
from potential collaborators; |
|
|
|
|
cause us to abandon the development of the affected product candidate; or |
|
|
|
|
limit our ability to obtain additional financing on acceptable terms, if at all. |
If third parties successfully assert that we have infringed their patents and proprietary rights or challenge the validity of our patents and proprietary rights, we may become involved in intellectual property disputes and litigation that would be costly, time consuming, and delay or prevent development or commercialization of our product candidates.
We may be exposed to future litigation by third parties based on claims that our product
candidates, proprietary technologies or the licenses on which we rely, infringe their intellectual
property rights, or we may be required to enter into litigation to enforce patents issued or
licensed to us or to determine the scope or validity of another partys proprietary rights. If we
become involved in any litigation, interference or other administrative proceedings related to our
intellectual property or the intellectual property of others, we will incur substantial expenses
and it will divert the efforts of our technical and management personnel. Others may succeed in
challenging the validity of our issued and pending claims.
Two of our potential competitors relative to HEPLISAV, Merck & Co., Inc. and GlaxoSmithKline
Plc, are exclusive licensees of broad patents covering hepatitis B surface antigen. In addition,
the Institute Pasteur also owns or has exclusive licenses to patents covering hepatitis B surface
antigen. While some of these patents have expired or will soon expire outside of the United States,
they remain in force in the United States and are likely to be in force when we commercialize
HEPLISAV or a similar product in the United States. To the extent we were to commercialize HEPLISAV
in the United States, Merck and/or GlaxoSmithKline or the Institute Pasteur may bring claims
against us.
If we are unsuccessful in defending or prosecuting our issued and pending claims or in
defending potential claims against us, for example, as may arise to the extent we were to
commercialize HEPLISAV or any similar product candidate in the United States, we could be required
to pay substantial damages and we may be unable to commercialize our product candidates or use our
proprietary technologies unless we obtain a license from these or other third parties. A license
may require us to pay substantial royalties, require us to grant a cross-license to our technology
or may not be available to us on acceptable terms or on any terms. In addition, we may be required
to redesign our technology so it does not infringe a third partys patents, which may not be
possible or could require substantial funds and time. Any of these outcomes may require us to
change our business strategy and could reduce the value of our business.
Another of our potential competitors, Coley Pharmaceutical Group (Coley), has issued U.S.
patent claims, as well as patent claims pending with the U.S. Patent and Trademark Office, that, if
held to be valid, could require us to obtain a license in order to commercialize one or more of our
formulations of ISS in the United States, including TOLAMBA and HEPLISAV. In December 2003 the U.S.
Patent and Trademark Office declared an interference to resolve first-to-invent disputes between a
patent application filed by the Regents of the University of California, which is exclusively
licensed to us, and an issued U.S. patent owned by Coley relating to immunostimulatory DNA
sequences. The declaration of interference named the Regents of the University of California as
senior party, indicating that a patent application filed by the Regents of the University of
California and licensed to us was filed prior to a patent application owned by Coley that led to an
issued U.S. patent. The interference provides the first forum to challenge the validity and
priority of certain of Coleys patents. On March 10, 2005, the
21
U.S. Patent and Trademark Office
issued a decision in the interference which did not address the merits of the case, but dismissed
it on a legal technicality related to the timing of Dynavaxs
filing of its claims and request for interference. Dynavax has appealed this non-final decision. If
we prevail in the appeal, we will be able to continue the interference to address the merits of the
case. If we prevail in the interference proceeding, it would establish our founders as the
inventors of the inventions in dispute. However, even a favorable outcome in the interference would
not prevent Coley from asserting its other patents or patent claims, that were not the subject of
the interference, against our ISS products, which could harm our ability to commercialize those
products. If we do not prevail in the interference proceeding, we may not be able to obtain patent
protection on the subject matter of the interference, which would have a material adverse impact on
our business. In addition, if Coley prevails in the interference, it may seek to enforce its rights
under issued claims, including, for example, by suing us for patent infringement. Consequently, we
may need to obtain a license to issued and/or pending claims held by Coley by paying cash, granting
royalties on sales of our products or offering rights to our own proprietary technologies. Such a
license may not be available to us on acceptable terms, if at all.
If we receive regulatory approval for our product candidates, we will be subject to ongoing FDA and foreign regulatory obligations and continued regulatory review, which may be costly and subject us to various enforcement actions.
Any regulatory approvals that we receive for our product candidates are likely to contain
requirements for post-marketing follow-up studies, which may be costly. Product approvals, once
granted, may be modified, resulting in limitations on our labeling indications or marketing claims,
or withdrawn completely if problems occur after commercialization. Thus, even if we receive FDA and
other regulatory approvals, our product candidates may later exhibit qualities that limit or
prevent their widespread use or that force us to withdraw those products from the market.
In addition, we or our contract manufacturers will be required to adhere to federal
regulations setting forth current good manufacturing practice. The regulations require that our
product candidates be manufactured and our records maintained in a prescribed manner with respect
to manufacturing, testing and quality control activities. Furthermore, we or our contract
manufacturers must pass a pre-approval inspection of manufacturing facilities by the FDA and
foreign regulatory agencies before obtaining marketing approval and will be subject to periodic
inspection by the FDA and corresponding foreign regulatory agencies under reciprocal agreements
with the FDA. Further, to the extent that we contract with third parties for the manufacture of our
products, our ability to control third-party compliance with FDA requirements will be limited to
contractual remedies and rights of inspection.
Failure to comply with regulatory requirements could prevent or delay marketing approval or
require the expenditure of money or other resources to correct. Failure to comply with applicable
requirements may also result in warning letters, fines, injunctions, civil penalties, recall or
seizure of products, total or partial suspension of production, refusal of the government to renew
marketing applications and criminal prosecution, any of which could be harmful to our ability to
generate revenues and our stock price.
Our product candidates in clinical trials rely on a single lead ISS compound, 1018 ISS, and most of our earlier stage programs rely on ISS-based technology. Serious adverse safety data relating to either 1018 ISS or other ISS-based technology may require us to reduce the scope of or discontinue our operations.
Our product candidates in clinical trials are based on 1018 ISS, and substantially all of our
research and development programs use ISS-based technology. If any of our product candidates in
clinical trials produce serious adverse safety data, we may be required to delay or discontinue all
of our clinical trials. In addition, as all of our clinical product candidates contain 1018 ISS,
potential collaborators may also be reluctant to establish collaborations for our products in
distinct therapeutic areas due to the common safety risk across therapeutic areas. If adverse
safety data are found to apply to our ISS-based technology as a whole, we may be required to
discontinue our operations.
A key part of our business strategy is to establish collaborative relationships to commercialize and fund development of our product candidates. We may be unsuccessful in establishing and managing collaborative relationships, which may significantly limit our ability to develop and commercialize our products successfully, if at all.
We will need to establish collaborative relationships to obtain domestic and international
sales, marketing and distribution capabilities for our product candidates. We also intend to enter
into collaborative relationships to provide funding to support our research and development
programs. We have established a collaborative relationship with Berna Biotech for HEPLISAV, a
prophylactic vaccine, and for hepatitis B therapeutic product candidates. Our collaboration
agreement with UCB for TOLAMBA and for grass allergy immunotherapy ended in March 2005. Future
collaboration revenue will depend on our ability to enter into new collaborative relationships.
22
The process of establishing collaborative relationships is difficult,
time-consuming and involves significant uncertainty. Moreover, even if we do establish
collaborative relationships, our collaborators may seek to renegotiate or terminate their
relationships with us due to unsatisfactory clinical results, a change in business strategy, a
change of control or other reasons. If any collaborator fails to fulfill its responsibilities in a
timely manner, or at all, our research, clinical development or commercialization efforts related
to that collaboration could be delayed or terminated, or it may be necessary for us to assume
responsibility for expenses or activities that would otherwise have been the responsibility of our
collaborator. If we are unable to establish and maintain collaborative relationships on acceptable
terms, we may have to delay or discontinue further development of one or more of our product
candidates, undertake development and commercialization activities at our own expense or find
alternative sources of capital.
We rely on third parties to supply component materials necessary for our clinical product
candidates and manufacture product candidates for our clinical trials. Loss of these suppliers or
manufacturers, or failure to replace them may delay our clinical trials and research and
development efforts and may result in additional costs, which would preclude us from producing our
product candidates on commercially reasonable terms.
We rely on a number of third parties for the multiple steps involved in the manufacturing
process of our product candidates, including, for example, the manufacture of the antigens and ISS,
the component materials that are necessary for our product candidates, the combination of the
antigens and ISS, and the fill and finish. Termination or interruption of these relationships may
occur due to circumstances that are outside our control, resulting in higher cost or delays in our
product development efforts.
We and these third parties are required to comply with applicable current FDA good
manufacturing practice regulations and similar requirements in Canada and other foreign countries.
If one of these parties fails to maintain compliance with these regulations, the production of our
product candidates could be interrupted, resulting in delays and additional costs. Additionally,
these third parties must pass a preapproval inspection before we can obtain regulatory approval for
any of our product candidates.
In particular, we have relied on a single supplier to produce our ISS for clinical trials. ISS
is a critical component of both of TOLAMBA and HEPLISAV. To date, we have manufactured only small
quantities of ISS ourselves for research purposes. If we were unable to maintain or replace our
existing source for ISS, we would have to establish an in-house ISS manufacturing capability,
incurring increased capital and operating costs and delays in developing and commercializing our
product candidates. We or other third parties may not be able to produce ISS at a cost, quantity
and quality that are available from our current third-party supplier.
In addition, we do not currently have a contract manufacturer for TOLAMBA or sufficient
TOLAMBA to supply our potential commercial needs. We are currently manufacturing supplies of
TOLAMBA for the second year of our current clinical trial in ragweed allergic children. We intend
to enter into manufacturing agreements with one or more commercial-scale contract manufacturers to
produce additional supplies of TOLAMBA as required for new clinical trials and commercialization.
If we are unable to complete such agreements, we may be unable to commence and complete our
clinical trials in a timely fashion, and we would have to establish an internal commercial scale
manufacturing capability for TOLAMBA, incurring increased capital and operating costs, delays in
the commercial development of TOLAMBA and higher manufacturing costs than we have experienced to
date.
We have or intend to contract with one or more third parties to conduct our clinical trials for
TOLAMBA and HEPLISAV. If these third parties do not carry out their contractual obligations or meet
expected deadlines, our planned clinical trials may be delayed and we may fail to obtain the
regulatory approvals necessary to commercialize TOLAMBA or HEPLISAV.
We are unable to independently conduct our planned clinical trials for TOLAMBA or HEPLISAV,
and we have or intend to contract with third party contract research organizations to manage and
conduct these trials. If these third parties do not carry out their contractual duties or
obligations or meet expected deadlines, if the third parties need to be replaced or if the quality
or accuracy of the clinical data they obtain is compromised due to failure to adhere to our
clinical protocols or for other reasons, our planned clinical trials may be extended, delayed or
terminated. Any extension, delay or termination of our trials would delay our ability to
commercialize TOLAMBA or HEPLISAV and generate revenues.
If any products we develop are not accepted by the market or if regulatory agencies limit our
labeling indications or marketing claims, we may be unable to generate significant revenues, if
any.
We do not anticipate that any of our product candidates will be commercially available until
2008 at the earliest, if at all. Furthermore, even if we obtain regulatory approval for our product
candidates and are able to successfully commercialize them, our product candidates may not gain
market acceptance among physicians, patients, health care payors and the medical community. The FDA
or other regulatory agencies could limit the labeling indication for which our product candidates
may be marketed or could otherwise constrain our marketing claims,
23
reducing our or our collaborators ability to market the
benefits of our products to particular patient populations. If we are unable to successfully market
any approved product candidates, or are limited in our marketing efforts by regulatory limits on
labeling indications or marketing claims, our ability to generate revenues could be significantly
impaired.
In particular, treatment with TOLAMBA, if approved, will require a series of injections, and
we expect that some of the patients that currently take oral or inhaled pharmaceutical products to
treat their allergies would not consider using our product. We believe that market acceptance of
TOLAMBA will also depend on our ability to offer competitive pricing, increased efficacy and
improved ease of use as compared to existing or potential new allergy treatments.
We may seek partners for purposes of commercialization of HEPLISAV in selected markets
worldwide in addition to or as a replacement for our current collaborative partner, Berna Biotech.
Berna Biotech has an exclusive option to commercialize HEPLISAV and therapeutic product candidates.
Marketing challenges vary by market and could limit or delay acceptance in any particular country.
We believe that market acceptance of HEPLISAV will depend on our ability to offer increased
efficacy and improved ease of use as compared to existing or potential new hepatitis B vaccine
products.
We face uncertainty related to coverage, pricing and reimbursement and the practices of third party
payors, which may make it difficult or impossible to sell our product candidates on commercially
reasonable terms.
In both domestic and foreign markets, our ability to generate revenues from the sales of any
approved product candidates in excess of the costs of producing the product candidates will depend
in part on the availability of reimbursement from third party payors. Existing laws affecting the
pricing and coverage of pharmaceuticals and other medical products by government programs and other
third party payors may change before any of our product candidates are approved for marketing. In
addition, third party payors are increasingly challenging the price and cost-effectiveness of
medical products and services. Significant uncertainty therefore exists as to coverage and
reimbursement levels for newly approved health care products, including pharmaceuticals. Because we
intend to offer products, if approved, that involve new technologies and new approaches to treating
disease, the willingness of third party payors to reimburse for our products is particularly
uncertain. We will have to charge a price for our products that is sufficiently high to enable us
to recover the considerable capital resources we have spent and will continue to spend on product
development. Adequate third-party reimbursement may not be available to enable us to maintain price
levels sufficient to realize a return on our investment in product development. If it becomes
apparent, due to changes in coverage or pricing of pharmaceuticals in our market or a lack of
reimbursement, that it will be difficult, if not impossible, for us to generate revenues in excess
of costs, we will need to alter our business strategy significantly. This could result in
significant unanticipated costs, harm our future prospects and reduce our stock price.
Many of our competitors have greater financial resources and expertise than we do. If we are unable
to successfully compete with existing or potential competitors despite these disadvantages we may
be unable to generate revenues and our business will be harmed.
We compete with many companies and institutions, including pharmaceutical companies,
biotechnology companies, academic institutions and research organizations, in developing
alternative therapies to treat or prevent allergy, infectious diseases, asthma and cancer, as well
as those focusing more generally on the immune system. Competitors may develop more effective, more
affordable or more convenient products or may achieve earlier patent protection or
commercialization of their products. These competitive products may render our product candidates
obsolete or limit our ability to generate revenues from our product candidates. Many of the
companies developing competing technologies and products have significantly greater financial
resources and expertise in research and development, manufacturing, preclinical and clinical
testing, obtaining regulatory approvals and marketing than we do.
TOLAMBA, if approved, will compete directly with conventional allergy shots and indirectly
with antihistamines, corticosteroids and anti-leukotriene agents, used to treat seasonal allergy
symptoms, including those produced by GlaxoSmithKline Plc, Merck & Co., Inc. and AstraZeneca Plc.
Since our TOLAMBA ragweed allergy treatment would require a series of injections, we expect that
some patients that currently take oral or inhaled pharmaceutical products to treat their allergies
would not consider our product.
HEPLISAV, if approved, will compete with existing vaccines produced by GlaxoSmithKline Plc and
Merck & Co., Inc., among others.
Existing and potential competitors may also compete with us for qualified scientific and
management personnel, as well as for technology that would be advantageous to our business. If we
are unable to compete with existing and potential competitors we may not be able to obtain
financing, sell our product candidates or generate revenues.
24
We depend on key employees in a competitive market for skilled personnel, and the loss of the
services of any of our key employees would affect our ability to develop and commercialize our
product candidates and achieve our objectives.
We are highly dependent on the principal members of our management, operations and scientific
staff, including our Chief Executive Officer, Dino Dina. We experience intense competition for
qualified personnel. Our future success also depends in part on the continued service of our
executive management team, key scientific and management personnel and our ability to recruit,
train and retain essential scientific personnel for our drug discovery and development programs,
including those who will be responsible for overseeing our preclinical testing and clinical trials
as well as for the establishment of collaborations with other companies. If we lose the services of
any of these people, our research and product development goals, including the identification and
establishment of key collaborations, operations and marketing efforts could be delayed or
curtailed.
We intend to develop, seek regulatory approval for and market our product candidates outside the
United States, requiring a significant commitment of resources. Failure to successfully manage our
international operations could result in significant unanticipated costs and delays in regulatory
approval or commercialization of HEPLISAV and therapeutic product candidates.
We plan to introduce HEPLISAV initially in various markets outside the United States.
Developing, seeking regulatory approval for and marketing our product candidates outside the United
States could impose substantial burdens on our resources and divert managements attention from
domestic operations. We may also conduct operations in other foreign jurisdictions.
International operations are subject to risk, including:
|
|
|
the difficulty of managing geographically distant operations, including
recruiting and retaining qualified employees, locating adequate facilities and establishing
useful business support relationships in the local community; |
|
|
|
|
compliance with varying international regulatory requirements; |
|
|
|
|
securing international distribution, marketing and sales capabilities; |
|
|
|
|
adequate protection of our intellectual property rights; |
|
|
|
|
difficulties and costs associated with complying with a wide variety of complex international laws and treaties; |
|
|
|
|
legal uncertainties and potential timing delays associated with tariffs, export licenses and other trade barriers; |
|
|
|
|
adverse tax consequences; |
|
|
|
|
the fluctuation of conversion rates between foreign currencies and the U.S. dollar; and |
|
|
|
|
geopolitical risks. |
If we are unable to successfully manage our international operations, we may incur significant
unanticipated costs and delays in regulatory approval or commercialization of HEPLISAV and
therapeutic product candidates, as well as other product candidates that we may choose to
commercialize internationally, which would impair our ability to generate revenues.
We use hazardous materials in our business. Any claims or liabilities relating to improper
handling, storage or disposal of these materials could be time consuming and costly to resolve.
Our research and product development activities involve the controlled storage, use and
disposal of hazardous and radioactive materials and biological waste. We are subject to federal,
state and local laws and regulations governing the use, manufacture, storage, handling and disposal
of these materials and certain waste products. We are currently in compliance with all government
permits that are required for the storage, use and disposal of these materials. However, we cannot
eliminate the risk of accidental contamination or injury to persons or property from these
materials. In the event of an accident related to hazardous materials, we could be held liable for
damages, cleanup costs or penalized with fines, and this liability could exceed the limits of our
insurance policies and exhaust our internal resources. We may have to incur significant costs to
comply with future environmental laws and regulations.
25
We face product liability exposure, which, if not covered by insurance, could result in significant
financial liability.
While we have not experienced any product liability claims to date, the use of any of our
product candidates in clinical trials and the sale of any approved products will subject us to
potential product liability claims and may raise questions about a products safety and efficacy.
As a result, we could experience a delay in our ability to commercialize one or more of our product
candidates or reduced sales of any approved product candidates. In addition, a product liability
claim may exceed the limits of our insurance policies and exhaust our internal resources. We have
obtained limited product liability insurance coverage in the amount of $1 million for each
occurrence for clinical trials with umbrella coverage of an additional $4 million. This coverage
may not be adequate or may not continue to be available in sufficient amounts, at an acceptable
cost or at all. We also may not be able to obtain commercially reasonable product liability
insurance for any product approved for marketing in the future. A product liability claim, product
recalls or other claims, as well as any claims for uninsured liabilities or in excess of insured
liabilities, would divert our managements attention from our business and could result in
significant financial liability.
If the combination of patents, trade secrets and contractual provisions that we rely on to protect
our intellectual property is inadequate, the value of our product candidates will decrease.
Our success depends on our ability to:
|
|
|
obtain and protect commercially valuable patents or the rights to patents both domestically and abroad; |
|
|
|
|
operate without infringing upon the proprietary rights of others; and |
|
|
|
|
prevent others from successfully challenging or infringing our proprietary rights. |
We will be able to protect our proprietary rights from unauthorized use only to the extent
that these rights are covered by valid and enforceable patents or are effectively maintained as
trade secrets. We try to protect our proprietary rights by filing and prosecuting United States and
foreign patent applications. However, in certain cases such protection may be limited, depending in
part on existing patents held by third parties, which may only allow us to obtain relatively narrow
patent protection. In the United States, legal standards relating to the validity and scope of
patent claims in the biopharmaceutical field can be highly uncertain, are still evolving and
involve complex legal and factual questions for which important legal principles remain unresolved.
The biopharmaceutical patent environment outside the United States is even more uncertain. We
may be particularly affected by this uncertainty, given that several of our product candidates may
initially address market opportunities outside the United States. For example, we expect to market
HEPLISAV, if approved, in various foreign countries with high incidences of hepatitis B, including
Canada, Europe and selected markets in Asia, where we may only be able to obtain limited patent
protection.
The risks and uncertainties that we face with respect to our patents and other proprietary
rights include the following:
|
|
|
we might not have been the first to make the inventions covered by each of our
pending patent applications and issued patents; |
|
|
|
|
we might not have been the first to file patent applications for these
inventions; |
|
|
|
|
the pending patent applications we have filed or to which we have exclusive
rights may not result in issued patents or may take longer than we expect to result in
issued patents; |
|
|
|
|
the claims of any patents that are issued may not provide meaningful protection; |
|
|
|
|
our issued patents may not provide a basis for commercially viable products or may not be valid or enforceable; |
|
|
|
|
we might not be able to develop additional proprietary technologies that are patentable; |
|
|
|
|
the patents licensed or issued to us or our collaborators may not provide a competitive advantage; |
|
|
|
|
patents issued to other companies, universities or research institutions may harm our ability to do business; |
26
|
|
|
other companies, universities or research institutions may independently
develop similar or alternative technologies or duplicate our technologies and commercialize
discoveries that we attempt to patent; and |
|
|
|
|
other companies, universities or research institutions may design around
technologies we have licensed, patented or developed. |
We also rely on trade secret protection and confidentiality agreements to protect our
interests in proprietary know-how that is not patentable and for processes for which patents are
difficult to enforce. We
cannot be certain that we will be able to protect our trade secrets adequately. Any leak of
confidential data into the public domain or to third parties could allow our competitors to learn
our trade secrets. If we are unable to adequately obtain or enforce proprietary rights we may be
unable to commercialize our products, enter into collaborations, generate revenues or maintain any
advantage we may have with respect to existing or potential competitors.
We rely on our licenses from the Regents of the University of California. Impairment of these
licenses or our inability to maintain them would severely harm our business.
Our success depends upon our license arrangements with the Regents of the University of
California. These licenses are critical to our research and product development efforts. Our
dependence on these licenses subjects us to numerous risks, such as disputes regarding the
invention and corresponding ownership rights in inventions and know-how resulting from the joint
creation or use of intellectual property by us and the Regents of the University of California, or
scientific collaborators. Additionally, our agreements with the Regents of the University of
California generally contain diligence or milestone-based termination provisions. Our failure to
meet any obligations pursuant to these provisions could allow the Regents of the University of
California to terminate any of these licensing agreements or convert them to non-exclusive
licenses. In addition, our license agreements with the Regents of the University of California may
be terminated or may expire by their terms, and we may not be able to maintain the exclusivity of
these licenses. If we cannot maintain licenses that are advantageous or necessary to the
development or the commercialization of our product candidates, we may be required to expend
significant time and resources to develop or license similar technology.
Our stock price is subject to volatility, and your investment may suffer a decline in value.
The market prices for securities of biopharmaceutical companies have in the past been, and are
likely to continue in the future to be, very volatile. The market price of our common stock is
subject to substantial volatility depending upon many factors, many of which are beyond our
control, including:
|
|
|
progress or results of any of our clinical trials, in particular any
announcements regarding the progress or results of our planned Phase III trials for TOLAMBA
and HEPLISAV; |
|
|
|
|
progress of regulatory approval of our product candidates, in particular
TOLAMBA and HEPLISAV, and compliance with ongoing regulatory requirements; |
|
|
|
|
our ability to establish collaborations for the development and commercialization of our product candidates; |
|
|
|
|
market acceptance of our product candidates; |
|
|
|
|
our ability to raise additional capital to fund our operations, whether through the issuance of equity securities or debt; |
|
|
|
|
technological innovations, new commercial products or drug discovery efforts
and preclinical and clinical activities by us or our competitors; |
|
|
|
|
changes in our intellectual property portfolio or developments or disputes
concerning the proprietary rights of our products or product candidates; |
|
|
|
|
our ability to obtain component materials and successfully enter into
manufacturing relationships for our product candidates or establish manufacturing capacity
on our own; |
|
|
|
|
our ability to form strategic partnerships or joint ventures; |
27
|
|
|
maintenance of our existing licensing agreements with the Regents of the University of California; |
|
|
|
|
changes in government regulations; |
|
|
|
|
issuance of new or changed securities analysts reports or recommendations; |
|
|
|
|
general economic conditions and other external factors; |
|
|
|
|
actual or anticipated fluctuations in our quarterly financial and operating results; and |
|
|
|
|
degree of trading liquidity in our common stock |
One or more of these factors could cause a decline in the price of our common stock. In
addition, securities class action litigation has often been brought against a company following a
decline in the market price of its securities. This risk is especially relevant for us because we
have experienced greater than average stock price volatility, as have other biotechnology companies
in recent years. We may in the future be the target of similar litigation. Securities litigation
could result in substantial costs, and divert managements attention and resources, which could
harm our business, operating results and financial conditions.
Anti-takeover provisions of our certificate of incorporation, bylaws and Delaware law may prevent
or frustrate a change in control, even if an acquisition would be beneficial to our stockholders,
which could affect our stock price adversely and prevent attempts by our stockholders to replace or
remove our current management.
Provisions of our certificate of incorporation and bylaws may delay or prevent a change in
control, discourage bids at a premium over the market price of our common stock and adversely
affect the market price of our common stock and the voting or other rights of the holders of our
common stock. These provisions include:
|
|
|
authorizing our Board of Directors to issue additional preferred stock with
voting rights to be determined by the Board of Directors; |
|
|
|
|
limiting the persons who can call special meetings of stockholders; |
|
|
|
|
prohibiting stockholder actions by written consent; |
|
|
|
|
creating a classified board of directors pursuant to which our directors are elected for staggered three year terms; |
|
|
|
|
providing that a supermajority vote of our stockholders is required for
amendment to certain provisions of our certificate of incorporation and bylaws; and |
|
|
|
|
establishing advance notice requirements for nominations for election to our
Board of Directors or for proposing matters that can be acted on by stockholders at
stockholder meetings. |
In addition, we are subject to the provisions of the Delaware corporation law that, in
general, prohibit any business combination with a beneficial owner of 15% or more of our common
stock for five years unless the holders acquisition of our stock was approved in advance by our
Board of Directors.
We will continue to implement additional finance and accounting systems, procedures or controls as
we grow our business and organization and to satisfy new reporting requirements.
As a public company, we are required to comply with the Sarbanes-Oxley Act of 2002 and the
related rules and regulations of the SEC, including expanded disclosures and accelerated reporting
requirements and more complex accounting rules. Compliance with Section 404 of the Sarbanes-Oxley
Act of 2002 and other requirements will increase our costs and require additional management
resources. We may need to continue to implement additional finance and accounting systems,
procedures and controls as we grow our business and organization and to comply with new reporting
requirements. Compliance with Section 404 will apply in 2005, and Section 404 reporting will first
occur in our Form 10-K for our fiscal year ending December 31, 2005. There can be no assurance that
we will be able to complete a favorable assessment as to the adequacy of our internal control
reporting. If we are unable to obtain an unqualified report as to the effectiveness of our internal controls over
financial reporting, investors could lose confidence in the reliability of our internal controls
over financial reporting and the reliability of our financial statements, which could harm our business and could
adversely impact the market price of our common stock.
28
The adoption of Statement of Financial Accounting Standard No. 123R and changes to existing
accounting pronouncements, rules or practices may affect how we conduct our business and affect our
reported financial results.
On December 16, 2004, the Financial Accounting Standards Board issued Financial Accounting
Standard (FAS) No. 123R (revised 2004), Share-Based Payment which will require us to measure
compensation costs for all stock-based compensation at fair value. We will adopt FAS No. 123R as of
January 1, 2006. Adoption of FAS No. 123R will have a material impact on our financial statements,
as we will be required to record compensation expense in our statement of operations for stock
option grants and stock purchases under our employee stock purchase plan, rather than disclose the
impact on our net loss within our footnotes, as is our current practice. The impact of adoption of
FAS No. 123R cannot be predicted at this time because it will depend on levels of share-based
payments granted in the future. Changes to existing rules, current practices, or future changes, if
any, may adversely affect our reported financial results or the way we conduct our business.
29
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The primary objective of our investment activities is to preserve principal while at the same
time maximize the income we receive from our investments without significantly increasing risk.
Some of the securities that we invest in may have market risk. This means that a change in
prevailing interest rates may cause the principal amount of the investment to fluctuate. To
minimize this risk, we maintain our portfolio of cash equivalents and investments in a variety of
securities, including commercial paper, money market funds, government and non-government debt
securities and corporate obligations. Because of the short-term maturities of our cash equivalents
and marketable securities, we do not believe that an increase in market rates would have any
significant negative impact on the realized value of our investments.
Interest Rate Risk. We do not use derivative financial instruments in our investment
portfolio. Due to the short duration and conservative nature of our cash equivalents and marketable
securities, we do not expect any material loss with respect to our investment portfolio.
Foreign Currency Risk. We have no significant investments outside the U.S. and have nominal
transactional foreign currency risk because nearly all of our business is transacted in U.S.
dollars. As a result, we currently have little exposure to foreign exchange rate fluctuations.
ITEM 4. CONTROLS AND PROCEDURES
(a) Evaluation of disclosure controls and procedures
The Companys management, under the supervision and with the participation of the Companys
Chief Executive Officer (CEO) and Chief Financial Officer (CFO), performed an evaluation of the
effectiveness of the design and operation of the Companys disclosure controls and procedures as of
the end of the period covered by this report. Based on that evaluation, the CEO and CFO concluded
that the Companys disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e)
under the Securities Exchange Act of 1934 (the Exchange Act)) as of the end of period covered by
this report have been designed and are functioning effectively to provide reasonable assurance that
the information required to be disclosed by us in reports filed under the Exchange Act is recorded,
processed, summarized and reported within the time periods specified in SEC rules and forms. We
believe that a control system, no matter how well designed and operated, cannot provide absolute
assurance that the objectives of the control system are met, and no evaluation of controls can
provide absolute assurance that all control issues and instances of fraud, if any, within a company
have been detected.
(b) Changes in internal controls
No changes in the Companys internal control over financial reporting occurred during the
Companys last fiscal quarter that have materially affected, or are reasonably likely to materially
affect, the Companys internal control over financial reporting.
30
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
None.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
On February 24, 2004, we completed our initial public offering of 6,900,000 shares of common
stock, including 900,000 shares subject to the underwriters over-allotment option (which was
exercised in full) at a public offering price of $7.50 per share and realized an aggregate offering
price of $51.8 million. Our registration statement on Form S-1 (Reg. No. 333-109965) was declared
effective by the SEC on February 11, 2004. The underwriters for the initial public offering were
Bear, Stearns & Co. Inc., Deutsche Bank Securities Inc. and Piper Jaffray & Co.
We received net proceeds from the offering of approximately $46.5 million. These proceeds are
net of $3.6 million in underwriting discounts and commissions, $1.4 million in legal, accounting
and printing fees and $0.3 million in other expenses. We used $0.4 million of the net proceeds to
make a one-time cash payment to the University of California pursuant to the terms of several
license agreements with them. During 2004, the net proceeds were used for research and development
activities and general corporate purposes. We will retain broad discretion over the use of the net
proceeds received from our offering. The amount and timing of our actual expenditures may vary
significantly depending on numerous factors, such as the progress of our product candidate
development and commercialization efforts and the amount of cash used by our operations.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
None.
ITEM 5. OTHER INFORMATION
None.
31
ITEM 6. EXHIBITS
|
|
|
Exhibit |
|
|
Number |
|
Document |
3.1*
|
|
Amended and Restated Bylaws |
31.1*
|
|
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
31.2*
|
|
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
32.1*
|
|
Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
32.2*
|
|
Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
* Filed herewith
32
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934,
the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto due
authorized, in the City of Berkeley, State of California.
|
|
|
|
|
|
DYNAVAX TECHNOLOGIES CORPORATION
|
|
|
By: |
/s/ DINO DINA, M.D.
|
|
|
|
Dino Dina, M.D. |
|
|
|
President, Chief Executive Officer and Director
(Principal Executive Officer) |
|
|
Date:
November 11, 2005
|
|
|
|
|
|
|
|
|
By: |
/s/ DEBORAH A. SMELTZER
|
|
|
|
Deborah A. Smeltzer |
|
|
|
Vice President, Operations and
Chief Financial Officer
(Principal Financial Officer) |
|
|
Date:
November 11, 2005
|
|
|
|
|
|
|
|
|
By: |
/s/ TIMOTHY G. HENN
|
|
|
|
Timothy G. Henn |
|
|
|
Vice President, Finance and Administration and
Chief Accounting Officer
(Principal Accounting Officer) |
|
|
Date:
November 11, 2005
33